BBK Worldwide (BBK), a patient recruitment innovator for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries, announces a strategic alliance with CROèe.
The Japanese pharmaceutical market is the second largest individual market in the world, with sales of $60 billion, which constitutes 11% of global pharmaceutical sales. Despite Japan’s market size, it typically takes 2.5 years longer for a drug to come to market in Japan than in most other countries.
“One immediate result of the partnership will be the ability to offer research sponsors a more reliable process for site identification and selection. BBK’s physician database, the BIO NotifierSM, combined with CROèe’s patient database, will serve as a resource to help clinical trial sponsors quickly and efficiently find appropriate patients and investigators of which they had previously been unaware,” comments Sho Ando, President, CROèe. “I am looking forward to being able to introduce global standards of patient recruitment and analysis to the Japanese market, and to contribute to an increased public understanding of clinical research,” continues Ando.
The formation of the alliance further demonstrates BBK’s commitment to industry growth within the region, having established an office in Osaka, Japan in 2009. CROèe will join a network of companies that make up the BBK Worldwide Alliance – companies that have been vetted for their demonstrated ability to provide sophisticated patient recruitment services in their country or region. Under BBK’s direction, the members of the BBK Worldwide Alliance provide clients with the most extensive recruitment capabilities available in the world today.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.